UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
April 13, 2015
MUSCLEPHARM CORPORATION
(Exact name of registrant as specified in
its charter)
NEVADA |
|
000-53166 |
|
77-0664193 |
(State or other jurisdiction of
incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
4721 Ironton Street, Building A
Denver, Colorado 80239
(Address of principal executive offices)
(Zip Code)
(303) 396-6100
(Registrant’s telephone number, including
area code)
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).
On April 13, 2015,
MusclePharm Corporation issued a press release announcing that it has reached an agreement in principle
to resolve an investigation by the Securities and Exchange Commission. A copy of the press release, filed with this report as Exhibit
99.1, is incorporated herein by reference.
ITEM 9.01 |
FINANCIAL STATEMENTS AND EXHIBITS |
Exhibit No. |
|
|
|
|
|
99.1 |
|
MusclePharm Corporation Press Release issued April 13, 2015. |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
MUSCLEPHARM CORPORATION |
|
|
|
Dated: April 13, 2015 |
|
|
|
By: |
/s/
Brad J. Pyatt |
|
Name: |
Brad J. Pyatt |
|
Title: |
Chief Executive Officer |
Exhibit 99.1
MusclePharm
Reaches Agreement In Principle In SEC Investigation
Denver, CO – April 13, 2015 –MusclePharm
Corporation (OTCQB: MSLP), a scientifically driven, performance-lifestyle sports nutrition company, today announced that it has
reached an agreement in principle with the Securities and Exchange Commission (“SEC”) to resolve an investigation.
The Company first announced the investigation on September 30, 2013. Management believes that the terms of the agreement, if accepted,
would not have a material adverse effect on the Company’s financial condition or results of operations.
Brad Pyatt, the Company’s Chief
Executive Officer, stated, “We are pleased to have reached an agreement in principle with the SEC and look forward to moving
ahead with our business.”
The SEC Commissioners must still approve
the agreement, which was made with the staff of the Enforcement Division of the Denver Regional Office, and thus the terms are
not final.
Brad Pyatt, the Company’s Chief
Executive Officer, in his individual capacity, has also reached an agreement with the Denver Regional Office to resolve the investigation,
which agreement is also subject to approval by the SEC Commissioners. The Company is also aware that the SEC staff is considering
the possibility of proposing that the SEC Commissioners approve charges against certain former officers, in their individual capacity,
for violations of the federal securities laws. Under Nevada law, where the Company is incorporated, the Company may have future
obligations to indemnify those individuals for expenses in connection with those investigations and to advance funds to the individuals
for those expenses.
About MusclePharm
MusclePharm® is
a scientifically-driven, performance lifestyle company that currently develops, manufactures, markets and distributes branded
nutritional supplements. The company offers a complete range of powders, capsules, tablets and gels. Its portfolio of
recognized brands, including MusclePharm® Hybrid and Core Series, Arnold Schwarzenegger Series™ and
FitMiss™, are marketed and sold in more than 110 countries and available in over 35,000 retail outlets globally. These
clinically-proven and scientific nutritional supplements are developed through a six-stage research process utilizing the
expertise of leading nutritional scientists, doctors and universities. MusclePharm is the innovator of the sports nutrition
industry. For more information, visit www.musclepharm.com. Follow MusclePharm Corporation
on Facebook, Twitter, and Instagram.
To sign up to receive MusclePharm news
via email, please visit http://ir.musclepharmcorp.com/email-alerts
Forward-Looking Statements
This release contains forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities
and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements
and may often, but not always, be identified by the use of such words as “expects”, “anticipates”, “intends”,
“estimates”, “plans”, “potential”, “possible”, “probable”, “believes”,
“seeks”, “may”, “will”, “should”, “could” or the negative of such terms
or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties
inherent in the Company’s business. More detailed information about the Company and the risk factors that may affect the
realization of forward-looking statements is set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2014, the Company’s Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC,
copies of which may be obtained from the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events
or circumstances after the date hereof
# # #
Media:
Becky Warren
(916) 607-0129
bwarren@mercuryllc.com
Muscle Pharm (CE) (USOTC:MSLP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Muscle Pharm (CE) (USOTC:MSLP)
Historical Stock Chart
From Apr 2023 to Apr 2024